Salvat introduces a drug for acute external otitis in South East Asia
The Catalan pharmaceutical group has handed over the rights to Hyphens Pharma, leader in allergy and otorhinolaryngology in the area, with headquarters in Singapore.
BY BIOCAT
Laboratorios Salvat has conceded the exclusive rights to Hyphens Pharma for the commercialization of the drug Cetraxal® (ciprofloxacina) in Cambodia, Indonesia, Malaysia, Philippines, Singapore and Vietnam. Hyphens is responsible to obtain marketing authorizations in these countries, whereas the Catalan chemist will manufacture and supply the products. Financial details of the partnership were however not disclosed.
“We are very satisfied to conclude our partnership with Hyphens, one of the leading companies in allergy/ENT in the Asean region. Up to date, Cetraxal range has been successfully launched in more than 30 countries all over the world, and we feel that Hyphens is the right partner for bringing the product to the Asean markets, where external otitis is a common problem,” has commented Jordi Julve, CEO of Salvat. For his part, Lim See Wah, Managing Director of Hyphens remarked: “The innovative feature of Cetraxal® will help to advance the treatment for ear infection in both adult and young children, an area where there has been no advancement for some time.”
Cetraxal® (ciprofloxacin) has been successfully marketed for acute external otitis (AOE) in Europe since 1995. The United States Food and Drug Administration (US FDA) approved it in 2009. AOE most frequently affects children and is characterized by intense pain and inflammation in the ear canal. Cetraxal Plus® (ciprofloxacin and fluocinolone) has been launched within Cetraxal® family, it is a new antibiotic-steroid combination for treatment of acute diffuse external otitis.
With headquarters in Esplugues de Llobregat (Barcelona) and established in 1955, Salvat is a pharmaceutical group of private property that is present in more than 40 countries worldwide through agreements of license of its products, agreements of collaboration and development of the products of its pipeline and the direct commercialization in export markets.